Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beatriz Perdiguero

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2011
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primatesBarbara J Flynn, Kathrin Kastenmüller, Ulrike Wille-Reece, et al.
Journal of Virology|August 26, 2011
The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigensCarmen Elena Gómez, José Luis Nájera, Beatriz Perdiguero, et al.
Frontiers in Immunology|December 24, 2019
The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1Suresh C Raman, Ernesto Mejías-Pérez, Carmen E Gomez, et al.
Journal of Virology|October 31, 2014
Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particlesBeatriz Perdiguero, Carmen Elena Gómez, Victoria Cepeda, et al.
Plos One|April 11, 2018
Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunizationAlberto C Guardo, Carmen Elena Gómez, Vicens Díaz-Brito, et al.
Plos One|October 25, 2017
Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunizationAlberto C Guardo, Carmen Elena Gómez, Vicens Díaz-Brito, et al.
Plos One|April 27, 2012
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade CCarmen Elena Gómez, Beatriz Perdiguero, Victoria Jiménez, et al.
Plos One|February 25, 2011
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectorsEsther D Quakkelaar, Anke Redeker, Elias K Haddad, et al.
NPJ Vaccines|March 6, 2024
Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA ConsortiumLaura Marcos-Villar, Beatriz Perdiguero, Shubaash Anthiya, et al.
NPJ Vaccines|May 18, 2024
Author Correction: Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA ConsortiumLaura Marcos-Villar, Beatriz Perdiguero, Shubaash Anthiya, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2011
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primatesBarbara J Flynn, Kathrin Kastenmüller, Ulrike Wille-Reece, et al.
Journal of Virology|August 26, 2011
The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigensCarmen Elena Gómez, José Luis Nájera, Beatriz Perdiguero, et al.
Frontiers in Immunology|December 24, 2019
The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1Suresh C Raman, Ernesto Mejías-Pérez, Carmen E Gomez, et al.
Journal of Virology|October 31, 2014
Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particlesBeatriz Perdiguero, Carmen Elena Gómez, Victoria Cepeda, et al.
Plos One|April 11, 2018
Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunizationAlberto C Guardo, Carmen Elena Gómez, Vicens Díaz-Brito, et al.
Plos One|October 25, 2017
Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunizationAlberto C Guardo, Carmen Elena Gómez, Vicens Díaz-Brito, et al.
Plos One|April 27, 2012
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade CCarmen Elena Gómez, Beatriz Perdiguero, Victoria Jiménez, et al.
Plos One|February 25, 2011
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectorsEsther D Quakkelaar, Anke Redeker, Elias K Haddad, et al.
NPJ Vaccines|March 6, 2024
Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA ConsortiumLaura Marcos-Villar, Beatriz Perdiguero, Shubaash Anthiya, et al.
NPJ Vaccines|May 18, 2024
Author Correction: Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA ConsortiumLaura Marcos-Villar, Beatriz Perdiguero, Shubaash Anthiya, et al.
Pageof 7